Physician profile
Pablo Coss
NPI 1992151963
$18,294.76
in general payments reported to CMS, 2019-2025
12 companies · $2,383 in 2025
The $2,383 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.61 · 2021: $11K · 2022: $2,912 · 2023: $1,837 · 2024: $423 · 2025: $2,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,387 · Food and Beverage: $2,087 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,386.72 |
| Food and Beverage | $2,087.10 |
| Education | $168.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $12,332.54 | 2021-2025 | Vercise |
| Medtronic, INC. | $2,638.70 | 2021-2025 | Percept Pc Brainsense, Sensight |
| Sage Therapeutics, LLC | $1,971.70 | 2022 | |
| Acadia Pharmaceuticals INC | $381.81 | 2022-2023 | Nuplazid |
| Neurocrine Biosciences, INC. | $250.40 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $168.45 | 2024-2025 | |
| Insightec,INC | $145.84 | 2025 | Exablate |
| Abbott Laboratories | $129.02 | 2023 | Infinity |
| Acorda Therapeutics, INC | $120.05 | 2019-2023 | Inbrija |
| Mdd US Operations, LLC | $115.76 | 2025 | |
| Amneal Pharmaceuticals LLC | $27.10 | 2023 | Rytary |
| Ge Healthcare | $13.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Coss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.